AR053011A1 - Compuestos de heteroarilo como inhibidores del receptor p2y1, composiciones farmaceuticas que los contienen y su uso en la manufactura de un medicamento para el tratamiento de un trastorno tromboembolico - Google Patents

Compuestos de heteroarilo como inhibidores del receptor p2y1, composiciones farmaceuticas que los contienen y su uso en la manufactura de un medicamento para el tratamiento de un trastorno tromboembolico

Info

Publication number
AR053011A1
AR053011A1 ARP060100185A ARP060100185A AR053011A1 AR 053011 A1 AR053011 A1 AR 053011A1 AR P060100185 A ARP060100185 A AR P060100185A AR P060100185 A ARP060100185 A AR P060100185A AR 053011 A1 AR053011 A1 AR 053011A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
crfrf
heterocycle
carbon atoms
Prior art date
Application number
ARP060100185A
Other languages
English (en)
Inventor
James C Sutton
Zulan Pi
Rejean Ruel
Heureux Alexandre L
Carl Thibeault
Patrick Y S Lam
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR053011A1 publication Critical patent/AR053011A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de heteroarilo y análogos de los mismos, los cuales son inhibidores selectivos del receptor humano P2Y1. También diversas composiciones farmacéuticas de los mismos y uso en la fabricacion de medicamentos para el tratamiento de enfermedades en respuesta a la modulacion de la actividad del receptor P2Y1, tales como trastornos tromboembolicos. Reivindicacion 1: Un compuesto de la formula (1), o un estereoisomero, tautomero, sal farmacéuticamente aceptable, solvato, o fármaco del mismo, caracterizado porque: el anillo A es un heteroarilo de 5 a 6 miembros que comprende: átomos de carbono y 1-4 heteroátomos en el anillo seleccionados de N, NR11, S(O)p, y O, en donde el heteroarilo es sustituido con 0-4 R1; el anillo B es fenilo sustituido con 0-4 R7, piridilo sustituido con 0-3 R7, o tienilo sustituido con 0-2 R7; X es NH o NMe; Y es O u S; R1 es, independientemente cada vez que se presenta, F, Cl, Br, I, CF3, -CF2CF3, OCF3, -OCF2CF2H, -OCF2CF3, SiMe3, - (CRfRf)r-ORc, SRc, CN, NO2, -(CRfRf)r-NR12R13, -(CRfRf)r-C(O)Rc, -(CRfRf)r-CO2Rc, -(CRfRf)r-C(O)NR12R13, -C(O)NR14(CRfRf)tN12R13, -(CRfRf)r-OC(O)NR12R13, -(CRfRf)r-NR14C(O)NR12R13, -(CRfRf)r-NR14C(O)Rd, -(CRfRf)r-NR14C(O)ORh, -NR14(CRfRf)nC(O)Rd, - NR14CO(CRfRf)nORc, -(CH2)r-CR13(=NORc), -(CH2)r-C(NH2)(=NORc), -S(O)pNR12R13, -(CRfRf)r-NR14S(O)pNR12R13, -NR14SO2CF3, -NR14S(O)pRd, -S(O)2CF3, -S(O)Rd, -S(O)2Rd -OP(O)(OEt)2, -O(CH2)2OP(O)(OEt)2, 4,4,5,5-tetrametil-1,3,2-dioxaborolanilo, alquilo C1- 8 sustituido con 0-2 Ra, alquenilo C2-8 sustituido con 0-2 Ra, alquinilo C2-8 sustituido con 0-2 Ra, carbocicloC3-13-(CRfRf)r- substituido con 0-5 Rb, o (CRfRf)r-heterociclo de 5 a 10 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, NR11, O, y S(O)p, en donde el heterociclo es sustituido con 0-5 Rb; alternativamente, dos R1 se combinan con los átomos de carbono a los cuales se enlazan, forman un carbociclo o heterociclo de 5 a 7 miembros que comprende: átomos de carbono y 0-3 heteroátomos adicionales seleccionados de N, NR11, O, y S(O)p, 0-2 carbonilos, y 0-2 enlaces dobles, en donde el carbociclo o heterociclo es sustituido con 0-4 Rb; R5 es un -(CRfRf)n-carbocicloC3-10 substituido con 1-4 R5a, o un -(CRfRf)n-heterociclo de 5 a 10 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, NR11, O, y S(O)p, en donde el heterociclo es sustituido con 0-4 R5a; R5a es, independientemente cada vez que se presenta F, Cl, Br, I, -(CRiRi)r-ORc, SRc, CN, NO2, CF3, -CF2CF3, OCF3, -OCF2CF2H, -OCF2CF3, -NR12R13, -C(O)Rc, -C(O)ORc, -C(O)NR12R13, -NR14C(O)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd, -Si(Me)3, Si(alquilo C1-4)3, haloalquilo C1-4, haloalquiloxi C1-4, alquiloxi C1-4, alquiltio C1-4, alquiloC1-4-C(O), alquiloC1-4-O-C(O), alquiloC1-4-C(O)NH, alquilo C1-4 sustituido con 0-2 Ra, alquenilo C2-8 sustituido con 0-2 Ra, alquinilo C2-8 sustituido con 0-2 Ra, -(CRfRf)r-carbocicloC3-10 substituido con 0-3 Re, o -(CRfRf)r- heterociclo de 5 a 10 miembros que comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NR11, O, y S(O)p, en donde el heterociclo es sustituido con 0-3 Re; alternativamente, dos grupos R5a, junto con los átomos a los cuales se enlazan, forman un anillo carbocíclico o heterocíclico de 5 a 7 miembros que comprende: átomos de carbono y 0-2 heteroátomos seleccionados de N, NR11, O, y S(O)p, 0-1 carbonilo, y 0-3 enlaces dobles, en donde el anillo carbocíclico o heterocíclico es sustituido con 0-3 Re; R7 es, independientemente cada vez que se presenta, H, F, Cl, Br, I, OCF3, CF3, ORc, SRc, CN, NO2, -NR12R13, -C(O)Rc, -C(O)ORc, -C(O)NR12R13, -NR14C(O)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd, alquilo C1-8 substituido con 0-2 Ra, alquenilo C2.8 substituido con 0-2 Ra, alquinilo C2_8 substituido con 0-2 Ra, (CRfRf)r-carbocicloC3-10 sustituido con 0-3 Rb, o (CRfRf)r-heterociclo de 5 a 10 miembros que comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NR7b, O, y S(O)p, en donde el heterociclo es sustituido con 0-3 Rb; alternativamente, dos R7 pueden formar un anillo carbocíclico o heterocíclico de 5 a 7 miembros que comprende: átomos de carbono y 0-3 heteroátomos en el anillo seleccionados de O, N, NR7b, y S(O)p, en donde el anillo carbocíclico o heterocíclico es sustituido con 0-3 R7c; R7b es, independientemente cada vez que se presenta, H, alquilo C1-4, alquiloC1-4C(O)-, fenilo-C(O)-, bencilo-C(O)-, bencilo-S(O)2-, alquiloC1-4NHC(O)-, (alquiloC1-4)2NC(O)-, fenilo-NHC(O)-, bencilo-NHC(O)-, alquiloC1-4-S(O)2-, fenilo-S(O)2-, fenilo sustituido con 0-3 Rb, o bencilo sustituido con 0-3 Rb; R7c es, independientemente cada vez que se presenta, H, F, Cl, Br, I, OCF3, CF3, ORc, SRc, CN, NO2, -NR12R13, -C(O)Rc, -C(O)ORc, -C(O)NR12R13, -NR14C(O)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd, alquilo C1-4, fenilo sustituido con 0-3 Rb, o bencilo sustituido con 0-3 Rb; R11 es, independientemente cada vez que se presenta, H, alquilo C1-6 substituido con 1-5 fluor, -(CRfRf)rC(O)NR12R13, alquilo C1-8 substituido con 0-2 Ra, alquenilo C2-8 substituido con 0-2 Ra, alquinilo C2-8 substituido con 0-2 Ra, alquiloC1-6C(O)-, cicloalquiloC3-6-alquiloC1-3-C(O)-, cicloalquiloC3-6C(O)-, fenilo- C(O)-, bencilo-C(O)-, alquiloC1-6NHC(O)-, (alquiloC1-6)2NC(O)-, fenilo-NHC(O)-, bencilo-NHC(O)-, fenilo-alquiloC1-6NC(O)-, bencilo-alquiloC1-6NC(O)-, alquiloC1-4-S(O)2-, fenilo-S(O)2-, bencilo-S(O)2-, -(CRfRf)r-carbocicloC3-10, o -(CRfRf)r- heterociclo de 5 a 10 miembros que comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NRf, O, y S(O)p; en donde el fenilo, bencilo, carbociclo, y heterociclo son sustituidos con 0-3 Rb; R12 es, independientemente cada vez que se presenta, H, alquilo C1-6 substituido con 1-5 fluor, -(CRfRf)r-C(O)NRfRf, alquilo C1-6, alquiloC1-6C(O)-, alquiloC1-4OC(O)-, ariloC6-10-CH2-OC(O)-, ariloC6-10-CH2-C(O)-, alquiloC1-4-C(O)O-alquiloC1-4-OC(O)-, ariloC6-10-C(O)O-alquiloC1-4-OC(O)-, alquiloC1-6-NHC(O)-, ariloC6-10-NHC(O)-, (heteroarilo de 5 a 10 miembros)-NHC(O)-, (heteroarilo de 5 a 10 miembros)-CH2-OC(O)-, (heteroarilo de 5 a 10 miembros)-C(O)-, ariloC6-10-alquiloC0-4-C(O)-, alquiloC 1-6-S(O)2-, ariloC6-10-S(O)2-, (heterorilo de 5 a 10 miembros)-S(O)2-, o ariloC6-10-alquiloC1-4-S(O)2-, -(CRfRf)n-ariloC6-10, -(CRfRf)n-heterociclo de 5 a 10 miembros; en donde el alquilo, fenilo y arilo son sustituidos con 0-2 Rg; el heteroarilo de 5 a 10 miembros es sustituido con 0-2 Rg y comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, NRf, O, y S(O)p; el heterociclo de 5 a 10 miembros es sustituido con 0-2 Rg y comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, NRf, O, y S(O)p; R13 es, independientemente cada vez que se presenta, H, alquilo C1-6, o -(CH2)n-fenilo; alternativamente, R12 y R13, cuando se enlazan al mismo nitrogeno, se combinan para formar un anillo heterocíclico de 5 a 10 miembros que comprenden: átomos de carbono y 1-2 heteroátomos adicionales seleccionados de N, NRf, O, y S(O)p; R14 es, independientemente cada vez que se presenta, H, alquilo C1-6, sustituido con 0-2 R14a, alquenilo C2-6 substituido con 0-2 R14a, alquinilo C2-6 substituido con 0-2 R14a, (CH2)r- carbocicloC3-10 substituido con 0-3 Rg, o (CH2)r-heterociclo de 5 a 10 miembros que comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NRf, O, y S(O)p, en donde el heterociclo es sustituido con 0-3 Rg; R14a es, independientemente cada vez que se presenta, H, alquilo C1-4, ORf, Cl, F, Br, I, =O, CF3, CN, NO2, NR12R13, -C(O)Rf, -C(O)ORf-, -C(O)NR12R13, o -S(O)pRf; Ra es, independiente cada vez que se presenta, H, F, OCF3, CF3, -(CRfRf)rORc, -(CRfRf)rSRc, CN, -(CRfRf)rNR12R13, - (CRfRf)rC(O)Rc, -(CRfRf)rC(O)ORc, -(CRfRf)r-C(O)NR12R13, -(CRfRf)r-NR14C(O)Rd -(CRfRf)rS(O)pNR12R13, -(CRfRf)rS(O)Rd, -(CRfRf)rS(O)2Rd, alquilo C1-4 substituido con 1-5 fluor, (CH2)r-carbocicloC3-10 substituido con 0-3 Re, o (CH2)r-heterociclo de 5 a 10 miembros que comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NRf, O, y S(O)p, en donde el heterociclo es sustituido con 0-3 Re; Rb es, independientemente cada vez que se presenta, H, =O, F, Cl, Br, I, -(CH2)r-ORc, SRc, CN, NO2, CF3, OCF3, -(CRfRf)rNR12R13, -C(O)Rc, -(CH2)r-C(O)ORc, -(CH2)r C(O)NR12R13, -NR14C(O)Rd, -S(O)PNR12R13, -S(O)Rd, -S(O)2Rd, haloalquilo C1-4, haloalquiloxi C1-4, alquilo C1-4 substituido con 0-2 Ra, alquenilo C2-6 substituido con 0-2 Ra, alquinilo C2-6 substituido con 0-2 Ra, (CH2)r-carbocicloC3-10 substituido con 0-3 Re, o (CH2)r-heterociclo de 5 a 10 miembros que comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NRf, O, y S(O)p, en donde el heterociclo es sustituido con 0-3 Re; Rc es, independientemente cada vez que se presenta, H, -OP(O)(OEt)2, alquilo C1-8 substituido con 0-2 Re, alquenilo C2-8 substituido con 0-2 Re, alquinilo C2-8 substituido con 0-2 Re, (CRfRf)r-cicloalquiloC3-8 substituido con 0-2 Re, (CRfRf)r-ariloC6-10 substituido con 0-2 Re, o (CRfRf)r-heterociclo de 5 a 10 miembros que comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NRf, O, y S(O)p, en donde el heterociclo es sustituido con 0-2 Re; Rd es, independientemente cada vez que se presenta, CF3, OH, alcoxi C1-4, alquilo C1-6, (CH2)r-carbocicloC3-10 substituido con 0-2 Re, o (CH2)r-heterociclo de 5 a 10 miembros que comprenden: átomos de carbono y 1-4 heteroátomos seleccionados de N, NRf, O, y S(O)p, en donde el heterociclo es sustituido con 0-2 Re; Re es, independientemente cada vez que se presenta, H, =O, -(CH2)r-ORf, F, Cl, Br, I, CN, NO2, -(CH2)r-NR12R13, -C(O)Rf, -(CH2)r-C(O)ORf, -NR14C(O)Rf, -(CH2)r-C(O)NR12R13, -SO2NR12R13, - NR14SO2NR12R13, -NR14SO2-alquiloC1-4, -NR14SO2CF3, -NR14SO2-fenilo, -S(O)2CF3, -S(O)p-alquiloC1-4, -S(O)p-fenilo, -(CF2)rCF3, Si(alquiloC1-4)3, alquilo C1-8 substituido con 0-2 Rg, alquenilo C2-8 substituido con 0-2 Rg, alquinilo C2-8 substituido con 0-2 Rg, (CH2)r-cicloalquiloC3-8 substituido con 0-2 Rg, (CH2)r-ariloC6-10 substituido con 0-2 Rg, o (CH2)r-heterociclo de 5 a 10 miembr
ARP060100185A 2005-01-19 2006-01-18 Compuestos de heteroarilo como inhibidores del receptor p2y1, composiciones farmaceuticas que los contienen y su uso en la manufactura de un medicamento para el tratamiento de un trastorno tromboembolico AR053011A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64528505P 2005-01-19 2005-01-19
US74931705P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
AR053011A1 true AR053011A1 (es) 2007-04-18

Family

ID=36579581

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100185A AR053011A1 (es) 2005-01-19 2006-01-18 Compuestos de heteroarilo como inhibidores del receptor p2y1, composiciones farmaceuticas que los contienen y su uso en la manufactura de un medicamento para el tratamiento de un trastorno tromboembolico

Country Status (13)

Country Link
US (2) US7645778B2 (es)
EP (1) EP1954696B1 (es)
JP (1) JP2008527043A (es)
KR (1) KR20070100894A (es)
AR (1) AR053011A1 (es)
AT (1) ATE499370T1 (es)
AU (1) AU2006206611A1 (es)
DE (1) DE602006020327D1 (es)
MX (1) MX2007008434A (es)
NO (1) NO20073665L (es)
PE (1) PE20061120A1 (es)
TW (1) TW200638934A (es)
WO (1) WO2006078621A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US7388021B2 (en) * 2004-05-12 2008-06-17 Bristol Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7816382B2 (en) * 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
ATE485269T1 (de) * 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
JP2008543972A (ja) 2005-06-27 2008-12-04 ブリストル−マイヤーズ スクイブ カンパニー 血栓症状の治療に有用なｐ２ｙ１受容体のｎ−結合複素環式アンタゴニスト
WO2007002634A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
CN101273022A (zh) * 2005-07-04 2008-09-24 雷迪博士实验室有限公司 作为ampk激活剂的噻唑衍生物
CN101384568B (zh) * 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
EP2007393B1 (en) * 2006-04-07 2013-08-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
TW200811164A (en) * 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP4941971B2 (ja) * 2007-01-29 2012-05-30 独立行政法人産業技術総合研究所 アルキルチオ置換含窒素複素環化合物の製造方法
JP2010519267A (ja) 2007-02-22 2010-06-03 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺微生物剤
JP5527923B2 (ja) * 2007-03-28 2014-06-25 公益財団法人相模中央化学研究所 パーフルオロアルキル基を有する複素環化合物およびその製造方法
EP2132203A1 (en) 2007-04-10 2009-12-16 Bristol-Myers Squibb Company Thiazolyl compounds useful as kinase inhibitors
EA019104B1 (ru) 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
NZ585236A (en) 2007-10-09 2012-03-30 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
AU2008313776B2 (en) * 2007-10-18 2013-12-05 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
WO2010012793A1 (en) * 2008-08-01 2010-02-04 Bayer Cropscience Sa Fungicide aminothiazole derivatives
CA2745266C (en) 2008-12-03 2018-04-10 Yue Xu Stem cell cultures
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
CN103180304B (zh) * 2010-08-10 2017-02-15 奥克泰塔治疗有限责任公司 噻唑烷二酮化合物的合成方法
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
WO2014081689A1 (en) 2012-11-20 2014-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
EP3082821A4 (en) * 2013-11-14 2017-06-07 Avista Pharma Solutions, Inc. Antiparasitic compounds
US10647675B2 (en) 2015-09-18 2020-05-12 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
DE102018113646B4 (de) 2018-06-07 2021-06-24 Helmholtz-Zentrum Dresden - Rossendorf E.V. 2-Phenoxypyridin-3-amin-Derivate und deren Verwendung
JP7409696B2 (ja) 2018-06-15 2024-01-09 ハンダ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤の塩およびその組成物
EP4094762A1 (en) 2021-05-25 2022-11-30 UCL Business Ltd Treatment of neurological indications
EP4095134A1 (en) 2021-05-25 2022-11-30 UCL Business Ltd Polycyclic compounds for the treatment of neurological indications

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3118888A (en) * 1964-01-21 Acylated s-triazines and process for their preparation
NL280954A (es) * 1961-07-14
US4179563A (en) * 1978-05-19 1979-12-18 Warner-Lambert Company 3-Aryloxy-substituted-aminopyridines and methods for their production
US4186199A (en) * 1978-11-02 1980-01-29 American Hoechst Corporation Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
JPS56166180A (en) * 1980-05-28 1981-12-21 Chugai Pharmaceut Co Ltd Dibenzoxazepine derivative and its preparation
JPS56167649A (en) 1980-05-30 1981-12-23 Chugai Pharmaceut Co Ltd Diphenyl ether derivative
US4663453A (en) * 1983-05-18 1987-05-05 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
US4761411A (en) 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
JPS62280847A (ja) 1986-05-30 1987-12-05 Konica Corp 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
US4840947A (en) 1986-10-14 1989-06-20 Hoechst-Roussel Pharmaceuticals, Inc. Antiinflammatory and analgesic piperidin-4-yl-tetracyclic benzodiazepines and use thereas
JP2577222B2 (ja) * 1987-04-10 1997-01-29 興和株式会社 新規な置換アニリド誘導体
JPH0339740A (ja) 1989-07-06 1991-02-20 Konica Corp 転写型熱現像カラー感光材料
JP2951434B2 (ja) 1991-04-18 1999-09-20 三菱製紙株式会社 電子写真感光体
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
JP3395285B2 (ja) 1993-10-06 2003-04-07 日本製紙株式会社 感熱記録体
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE4443641A1 (de) 1994-12-08 1996-06-13 Bayer Ag Substituierte Carbonsäureamide
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
JPH11502816A (ja) * 1995-03-20 1999-03-09 イーライ・リリー・アンド・カンパニー ５−置換−３−（１，２，３，６−テトラヒドロピリジン−４−イル）−および３−（ピペリジン−４−イル）−１ｈ−インドール類：新規５−ｈｔ▲下１ｆ▼アゴニスト
EP0860433B1 (en) * 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
BR9708347A (pt) * 1996-03-25 1999-08-03 Lilly Co Eli Compostos de tetrahidorbeta-carbonila
EP0929218A4 (en) 1996-10-30 2001-05-16 Univ North Carolina R2Y RECEPTOR ANTAGONISTS
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5858289A (en) 1997-02-24 1999-01-12 Global Consulting, Inc. Process for preparing compressed shape of ceramic fiber
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
AU744281B2 (en) * 1997-11-10 2002-02-21 Bristol-Myers Squibb Company Benzothiazole protein tyrosine kinase inhibitors
EP1047691A1 (en) 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
AU1939999A (en) 1997-12-22 1999-07-12 Bayer Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
WO2000020391A1 (fr) * 1998-10-06 2000-04-13 Dainippon Pharmaceutical Co., Ltd. Derives pyridine disubstitues en position 2,3, procede de preparation associe, compositions de medicament contenant ces derives, et intermediaires servant dans cette preparation
WO2000023420A1 (fr) 1998-10-20 2000-04-27 Takeda Chemical Industries, Ltd. Derives d'amine aromatique, procede de preparation de ces derives et agents les contenant
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EE04799B1 (et) * 1999-03-12 2007-04-16 Boehringer Ingelheim Pharmaceuticals, Inc. Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
ES2391550T3 (es) * 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
CO5200760A1 (es) 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
WO2001023358A1 (fr) 1999-09-27 2001-04-05 Sagami Chemical Research Center Derives pyrazole, intermediaires pour la preparation de ces derives, procedes de preparation des derives et intermediaires, et herbicides dont ces derives sont le principe actif
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ATE336492T1 (de) 2000-01-14 2006-09-15 Us Gov Health & Human Serv Methonocarbacycloalkylanaloga von nucleosiden
US20030065176A1 (en) * 2000-01-29 2003-04-03 Myung-Gyun Kang Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
SK12712002A3 (sk) 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
AU2000240570A1 (en) 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002235431B2 (en) * 2001-01-31 2005-04-14 P&G-Clairol, Inc. Novels couplers for use in oxidative hair dyeing
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
US6706711B2 (en) 2001-04-27 2004-03-16 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitor
US20040254185A1 (en) 2001-05-08 2004-12-16 Alexander Ernst Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2002325381A1 (en) 2001-07-31 2003-02-24 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
NZ530782A (en) 2001-08-06 2005-11-25 Pharmacia Italia S Aminoisoxazole derivatives active as kinase inhibitors
RU2345993C2 (ru) 2001-09-21 2009-02-10 Бристол-Маерс Сквибб Компани ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
JP2005518365A (ja) * 2001-11-27 2005-06-23 メルク　エンド　カムパニー　インコーポレーテッド ４−アミノキノリン化合物
JP2003192587A (ja) 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
WO2003055848A2 (en) 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives as vr1- antagonists
WO2003068229A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP2324825A1 (en) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
DE10213228A1 (de) * 2002-03-25 2003-10-16 Bayer Ag Cyclopenten-Derivate
DE60335099D1 (de) * 2002-05-06 2011-01-05 Vertex Pharma Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
NZ537809A (en) 2002-08-01 2007-05-31 Neurosearch As 1-H-tetrazol-5-yl(phenyl) urea derivative compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
WO2004022529A2 (en) 2002-09-05 2004-03-18 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
JP2006507329A (ja) 2002-11-21 2006-03-02 ニューロサーチ、アクティーゼルスカブ 新規アリールウレイド安息香酸誘導体及びその使用
JPWO2004054617A1 (ja) * 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
TWM252710U (en) * 2003-07-18 2004-12-11 Huei-Chiun Shiu Annealing equipment
WO2005012221A1 (ja) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
JP2007502283A (ja) * 2003-08-13 2007-02-08 アムジェン インコーポレイテッド メラニン凝集ホルモン受容体アンタゴニスト
WO2005063293A1 (ja) 2003-12-26 2005-07-14 Masatoshi Hagiwara Sr蛋白質のリン酸化制御方法、および、sr蛋白質の活性制御剤を有効成分とする抗ウイルス剤
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7388021B2 (en) * 2004-05-12 2008-06-17 Bristol Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP4319958B2 (ja) 2004-09-15 2009-08-26 株式会社グリーンセイジュ 蒸留水製造システム
JP2008543972A (ja) * 2005-06-27 2008-12-04 ブリストル−マイヤーズ スクイブ カンパニー 血栓症状の治療に有用なｐ２ｙ１受容体のｎ−結合複素環式アンタゴニスト
US7816382B2 (en) * 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
ATE485269T1 (de) * 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002634A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

Also Published As

Publication number Publication date
WO2006078621A9 (en) 2008-06-19
WO2006078621A2 (en) 2006-07-27
US7645778B2 (en) 2010-01-12
NO20073665L (no) 2007-10-18
MX2007008434A (es) 2007-07-25
EP1954696A2 (en) 2008-08-13
EP1954696B1 (en) 2011-02-23
KR20070100894A (ko) 2007-10-12
WO2006078621A3 (en) 2006-10-05
AU2006206611A1 (en) 2006-07-27
PE20061120A1 (es) 2006-10-13
WO2006078621B1 (en) 2006-10-26
US8273772B2 (en) 2012-09-25
ATE499370T1 (de) 2011-03-15
US20060173002A1 (en) 2006-08-03
DE602006020327D1 (de) 2011-04-07
JP2008527043A (ja) 2008-07-24
TW200638934A (en) 2006-11-16
US20100093689A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
AR053011A1 (es) Compuestos de heteroarilo como inhibidores del receptor p2y1, composiciones farmaceuticas que los contienen y su uso en la manufactura de un medicamento para el tratamiento de un trastorno tromboembolico
AR047449A1 (es) Amino-benzazoles como inhibidores del receptor p2y1, composiciones farmaceuticas y metodos de tratamiento
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
AR056867A1 (es) Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
RU2015133450A (ru) Соединения имидазопиридина и их применение
JP2018524390A5 (es)
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
ATE517882T1 (de) Chinolinderivate
HRP20090468T1 (hr) Urea antagonisti p2y1 receptora korisni u liječenju trombotičkih stanja
AR086676A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa
AR055344A1 (es) Derivados de 1-oxoindano y 1-oxo-2,3-dihidroisoindol como inhibidores de p38, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la cinasa p38
ECSP056115A (es) ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA
AR095371A1 (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos
AR067412A1 (es) Moduladores de propiedades farmaceuticas de productos terapeuticos
JP2013509392A5 (es)
AR065531A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas.
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
BR112015014433A2 (pt) compostos tricíclicos
AR045913A1 (es) Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
ES2711075T3 (es) Compuestos para su uso en el tratamiento de trastornos cognitivos
AR054888A1 (es) Derivados de quinolina como agentes antibacterianos
JP2022501434A (ja) 血液癌を治療するための併用療法

Legal Events

Date Code Title Description
FB Suspension of granting procedure